• ResMed reports strong revenue growth in Sleep and Breathing Health and Residential Care Software segments
• Gross margins and operating income improved year-over-year
• Solid cash flow generation and balance sheet position

ResMed Inc. reported its financial results for the second quarter of fiscal year 2026. The company reported total revenue of $1.42 billion, an increase of 11% compared to the prior year period. Revenue from the Sleep and Breathing Health segment grew 12% to $1.26 billion, while revenue from the Residential Care Software segment increased 7% to $167 million. Gross profit margin improved to 61.8% from 58.6% in the prior year quarter, driven by operational efficiencies and favorable product mix. Operating income increased 18% to $492 million, with operating margin expanding to 34.6% from 32.5% a year ago. The company generated $797 million in cash flow from operations during the first half of fiscal 2026 and ended the quarter with a strong balance sheet, including $1.42 billion in cash and cash equivalents. ResMed also paid $175 million in dividends to shareholders during the first six months of the fiscal year.

For fiscal year 2026, ResMed expects revenue growth in the high single-digit to low double-digit percentage range and operating margin expansion compared to the prior year.

ResMed remains focused on driving innovation in its Sleep and Breathing Health and Residential Care Software businesses, while continuing to invest in research and development to maintain its market-leading position. The company is optimistic about its growth prospects, underpinned by favorable demographic and healthcare trends.